GPT-5.5 enters the lab: how OpenAI's new Rosalind update rewrites drug discovery

openai updated gpt-rosalind, a verticalized model for life sciences, by merging gpt-5.5’s agentic capabilities with deep domain expertise in areas like drug discovery and genomics. the release includes lifeslibench, a new benchmark judged by external experts to evaluate end-to-end performance on tasks ranging from data reconciliation to experimental troubleshooting. the model is currently available to eligible organizations via trusted-access deployment, focusing on high-stakes compliance and analysis workflows. this update underscores a trend toward specialized, tool-using models that can handle rigorous scientific evidence and quantitative biology.